Pfizer

This company is trending in the wrong direction…

This pandemic darling isn’t so popular anymore.

Dividends abound, even in the biotech sector…

Drug trial results can skyrocket valuations…

Its efforts to stop the virus have attracted attention…

The industry may have earned itself a grace period…

If the dollar tanks, you’ll want to be ready…

Watch as Marc reveals his process…

It’s never been more important to be selective…

We closed out a 228% gain…